This article was originally published in The Gray Sheet
Cardiovascular Imaging Systems receives FDA clearance to market the GuideView ultrasound imaging/delivery catheter. The 4 French GuideView incorporates the company's "common-lumen technology which allows low-profile therapeutic and imaging devices to use the distal portion of the catheter interchangeably." CVIS, which does not intend to market the device until late 1994, says it is evaluating use of the device with several angioplasty balloons, including Cordis' Orion and Advanced Cardiovascular Systems' Slalom. CVIS currently is concentrating on ramping up production of its MicroView 2.9 diagnostic catheter, which received FDA clearance on June 29. The company anticipates commercial distribution of the MicroView in October.
You may also be interested in...
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.
Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.